Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated a Neutral rating and $14.00 price target on Sarepta Therapeutics (NASDAQ: SRPT). The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
